Qidni Labs Inc. has developed a proprietary platform technology that provides high capacity for selective absorption and removal of uremic toxins and other solutes from large volumes of whole blood. The first application of this technology is in kidney blood dialysis. However, Qidni's platform technology can be modified for other applications for selective removal of target solutes and molecules from large volumes of whole blood and other biofluids.